OPENAI
Drug development gets an AI speed boost
Drug discovery is slow. Like, really slow. It can take scientists over a decade to get a treatment to market.
Time to bring in the bots!
Open AI just launched GPT-Rosalind, the first Life Sciences agent designed for biology workflows. (The model is named after Rosalind Franklin, a British chemist and unsung hero of DNA, whose X-ray photo helped confirm the landmark double-helix structure.)
Rosalind is built to expedite processes across biochemistry, drug discovery, and translational medicine. Or in plain terms, reduce the time between scientific breakthrough and bedside treatment.
Why this matters:
It currently takes anywhere from 10-15 years for new drugs to be approved.
Only ~10% of medications will pass US clinical trials.
Globally, over 300 million people with rare diseases are seeking better treatment options.
Not so fast
The good news? Rosalind will help speed up one of medicine's biggest bottlenecks. The reassuring news? Scientists will still lead the way.
So far, no fully AI-designed drug has made it through Phase 3 of clinical trials. And OpenAI has no intention of replacing expert guidance. This new model will simply allow researchers to move efficiently through their most tedious tasks.
That said, scientists are vocal about safety concerns. More than 100 experts have requested tighter controls over biological data, citing the risk of misuse in engineering dangerous pathogens.
OpenAI’s response is a limited rollout through their “trusted access program” and restricting Rosalind to highly-vetted organizations. (At least for now.) Some early partners include Amgen, Moderna, Thermo Fisher Scientific, and the Allen Institute.
Same scientific method, just with a shorter wait time.
Mitochondria is the powerhouse of the cell. But Rosalind is the horsepower of the lab. -TL
Vote for live results and see results + opinions from yesterday at the bottom of the email.